Article Versions Notes

Pintar Š, Hanžel J, Drobne D, Koželj M, Kurent T, Smrekar N, Novak G. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina. 2024; 60(2):296. https://doi.org/10.3390/medicina60020296

Pintar, Špela, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, and Gregor Novak. 2024. "Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease" Medicina 60, no. 2: 296. https://doi.org/10.3390/medicina60020296

Pintar, Š., Hanžel, J., Drobne, D., Koželj, M., Kurent, T., Smrekar, N., & Novak, G. (2024). Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina, 60(2), 296. https://doi.org/10.3390/medicina60020296